Questionnaire

1. There is a window of opportunity in the RA disease continuum during which early reduction of inflammation halts/reduces the progression of deformity over time.

2. In cases of clinically suspect arthralgia:

3. Patients for whom RF is a non-specific marker for RA include:

4. Early DMARD therapy changes the setpoint of the disease continuum by reducing inflammation, progression of joint damage, extra-articular and comorbid diseases, as well as mortality.

5. When initiating a DMARD as part of a treat-to-target strategy, escalation of treatment is recommended if a predefined target is not met within:

6. The SARAA-recommended standard first-line therapy for the management of RA is:

7. For the treatment of RA, corticosteroid therapy:

8. A bDMARD used for the management of RA is:

9. A tsDMARD (JAKi) that is used for the management of RA is:

10. In light of the risk of serious infections with the use of any b/tsDMARDs it is important that, prior to initiation of therapy, the patient is:

11. It may be necessary to interrupt b/tsDMARD therapy in patients who:

12. A major risk factor for the development of RA is:

13. SARAA recommends that assessment of PsA activity includes:

14. Musculoskeletal and extra-articular manifestations of PsA disease activity drive treatment decisions that will address as many domains as possible, although other important considerations for the management of PsA are previous therapies, patient preference and the involvement of other diseases and comorbidities.

15. A therapy that should not be used in patients with axSpA is: